Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis. - Wikidata - wikimedia - TriplyDB

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

http://www.wikidata.org/entity/Q37729543

about

Transcript levels of major interleukins in relation to the clinicopathological profile of patients with tuberculous intervertebral discs and healthy controls.Severe bacterial sepsis results in delayed diagnosis of tuberculous lymphadenitis in a rheumatoid arthritis patient treated with adalimumab.

P2860

Q31168480-B9A7E7CD-BD1C-4A5A-AF56-43ED1C206966 Q55253008-0949F692-86BF-4CE6-AD49-7BB7739C25CE

P2860

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

http://www.wikidata.org/entity/Q37729543

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 April 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

@en

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

@nl

type

label

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

@en

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

@nl

prefLabel

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

@en

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

@nl

P1433

Q37729543-4B8E8B2E-019A-4A7B-A325-7B6F73E9D5B6

P1476

Q37729543-407D4E20-5072-4496-AAD5-2CA324931C2F

P2093

Q37729543-1C657CF3-C780-4098-B87C-93FFCE822243

Q37729543-291A8756-6416-4C0B-99C6-B67A46E05991

Q37729543-402DCF57-A4B3-4206-8C5D-722D6330640B

Q37729543-63589BA2-233F-4583-9396-D24FF7DF213D

Q37729543-9392697B-FB7F-4674-8571-ADC616492443

Q37729543-A560CC27-31DB-4F60-97B3-BBEC36B4B6E0

P2860

Q37729543-0A482996-8A5D-4CCA-AC3B-5A60050BD63A

Q37729543-0FC7BB8C-64C9-4263-BD0D-CD49F2C09C1E

Q37729543-1186D7BC-C429-464B-B45E-6797FADB0D46

Q37729543-14D7B377-E9DC-4C06-8F5A-0EAAA77B5B06

Q37729543-1C0CFB82-F0FD-40E6-8947-5F3E41D41E9F

Q37729543-1C5DEACC-818E-4DAF-A6E2-64D847D8AFBC

Q37729543-24B5FA3F-38BC-47E4-B566-9BF7A868E96E

Q37729543-261F74B1-C49E-4D71-A516-A125C8651169

Q37729543-2721B08D-72FC-4768-A1BB-16189CA9E1A6

Q37729543-2F9338E0-BAA2-4829-B535-E3BCAAB3DEBA

P304

Q37729543-4E1D1D67-4296-470B-92E3-3E372946095F

P31

Q37729543-D3A0E02A-140D-457A-AC04-B5F3B3A5F8A1

P356

Q37729543-6CA20CDB-AEC7-4DFD-985D-F7FFAE2E4A56

P478

Q37729543-F72DBD58-C00E-4175-9C6B-4E98BEA20BCA

P577

Q37729543-0A3256EB-D471-4009-82B2-F5E431EEBB9A

P5875

Q37729543-7AFA783A-8D1F-48AD-98D0-84D12D55DF19

P698

Q37729543-7EED1551-6B00-4538-981F-05FF86FAD9E9

P921

Q37729543-4474A48A-3C4D-468F-AC6A-2564E84A91E9

Q37729543-7024CE96-34B2-4282-866F-B95EC07E4F1B

Q37729543-D70680A8-656A-4A39-BF4E-1DBF018DA179

P932

Q37729543-C503958E-807A-42EF-8786-75B28B0F39A3

P356

P1433

Biologics: Targets and Therapy

P1476

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

@en

P2093

Basheer Y Khassawneh

http://www.w3.org/2001/XMLSchema#string

Khaldoon M Alawneh

http://www.w3.org/2001/XMLSchema#string

Khaldoun Bashaireh

http://www.w3.org/2001/XMLSchema#string

Mahmoud H Ayesh

http://www.w3.org/2001/XMLSchema#string

Mahmoud Smadi

http://www.w3.org/2001/XMLSchema#string

Salwa Shihadeh Saadeh

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon- release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials.

Validation of rheumatoid arthritis diagnoses in health care utilization data

Initiation of rheumatoid arthritis treatments and the risk of serious infections.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Anti-TNF-alpha therapies: the next generation.

P304

193-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S59574

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262021235

http://www.w3.org/2001/XMLSchema#string

P698

24790412

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

4003144

http://www.w3.org/2001/XMLSchema#string